|
 The Bott Cancer Center at Holy Redeemer Hospital and Medical Center is proud to provide advanced cancer care to our patients and community by offering a variety of cancer clinical trials. Cancer clinical trials are research studies in which people and health care professionals work together to improve cancer care. They provide answers to scientific questions and help to find better ways to prevent, diagnose, or treat cancer. People who choose to take part in cancer clinical trials have an opportunity to contribute to the advancement of cancer care, while receiving the latest treatment options from clinical experts.
Holy Redeemer Health System’s Institutional Review Board (IRB) supports the cancer clinical trials program by reviewing each clinical trial to ensure the study is conducted fairly and the rights and welfare of volunteer participants are protected. Holy Redeemer Health System’s IRB is made up of doctors, researchers, nurses, pharmacists, local leaders, and other members of the community who are committed to our goal to provide the highest quality of care to our community.
As a member of the Penn Cancer Network, Holy Redeemer is able to provide access to trials sponsored by the National Cancer Institute. In addition, through the membership with the Abramson Cancer Center at the University of Pennsylvania, we are able to provide access to select National Institute of Health supported clinical trials that have been developed by researchers at Penn.
Clinical trials are completely voluntary; participation is a personal decision that should be made by each individual in conjunction with their physician and family. Please speak with your doctor to find out if a clinical trial is right for you or your loved one.
If you are interested in learning more about clinical trials at the Bott Cancer Center, please speak with your doctor or call our Clinical Trials Office at 215-938-3551.
Holy Redeemer Hospital and Medical Center Clinical Trials
Collapse all | Expand all
Breast
PACCT-1/ TAILORx: Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment
E5103: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
WISER Sister Study: Women In Steady Exercise Research
Testicular
UPCC 10800: Inherited Genetic Variation and Predisposition to Testicular Germ Cell Tumor
Lung
E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)
Colon/Rectal
C80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab or Cetuximab (C225) for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
For more information on Clinical Trials, please visit the following websites:
National Cancer Institute
Oncolink
|